US 10,993,942 J1 (288th)
	Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Deepak Sampath; Wayne John Fairbrother; Christian Klein; Sari L. Heitner Enschede; Rod A. Humerickhouse; Andrew W. Roberts; and John F. Seymour
Assigned to ABBVIE INC.
Trial No. PGR2022-00023, Feb. 3, 2022
Post-Grant Review Certificate for Patent 10,993,942, issued May 4, 2021, Appl. No. 16/827,650, Mar. 23, 2020
Post-Grant Review Certificate issued Feb. 7, 2025